Clinical Trial Update: A Long-term, Post-marketing Safety Study of Palynziq in Patients With PKU (PALace)

View source ↗

Summary

This document outlines a long-term, post-marketing safety study of Palynziq in patients with phenylketonuria (PKU), and the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Phenylketonuria

Drugs mentioned

• PALYNZIQ (PEGVALIASE-PQPZ)

Snippet

Sponsor: BioMarin Pharmaceutical | Conditions: Phenylketonuria (PKU) | Status: RECRUITING